JP2008525477A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008525477A5 JP2008525477A5 JP2007548473A JP2007548473A JP2008525477A5 JP 2008525477 A5 JP2008525477 A5 JP 2008525477A5 JP 2007548473 A JP2007548473 A JP 2007548473A JP 2007548473 A JP2007548473 A JP 2007548473A JP 2008525477 A5 JP2008525477 A5 JP 2008525477A5
- Authority
- JP
- Japan
- Prior art keywords
- glp
- seq
- polypeptide
- formulation
- deleted mimetibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 64
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 63
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 63
- 108090000765 processed proteins & peptides Proteins 0.000 claims 44
- 229920001184 polypeptide Polymers 0.000 claims 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims 33
- 239000000203 mixture Substances 0.000 claims 26
- 238000009472 formulation Methods 0.000 claims 24
- 102000039446 nucleic acids Human genes 0.000 claims 22
- 108020004707 nucleic acids Proteins 0.000 claims 22
- 150000007523 nucleic acids Chemical class 0.000 claims 22
- 108060003951 Immunoglobulin Proteins 0.000 claims 21
- 239000004480 active ingredient Substances 0.000 claims 21
- 102000018358 immunoglobulin Human genes 0.000 claims 21
- 241001465754 Metazoa Species 0.000 claims 19
- 206010012601 diabetes mellitus Diseases 0.000 claims 19
- 210000000056 organ Anatomy 0.000 claims 18
- 210000001519 tissue Anatomy 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 16
- 229940079593 drug Drugs 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 8
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 8
- 208000030159 metabolic disease Diseases 0.000 claims 7
- 102000004877 Insulin Human genes 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 5
- 230000000975 bioactive effect Effects 0.000 claims 5
- 229940125396 insulin Drugs 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 5
- 108091033319 polynucleotide Proteins 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 210000003403 autonomic nervous system Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 241001260012 Bursa Species 0.000 claims 1
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000010836 blood and blood product Substances 0.000 claims 1
- 229940125691 blood product Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000005069 ears Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- -1 hormonal drugs Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 210000001331 nose Anatomy 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63831304P | 2004-12-22 | 2004-12-22 | |
| PCT/US2005/046602 WO2007046834A2 (en) | 2004-12-22 | 2005-12-22 | Glp-1 agonists, compositions, methods and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008525477A JP2008525477A (ja) | 2008-07-17 |
| JP2008525477A5 true JP2008525477A5 (enExample) | 2009-02-12 |
Family
ID=37962937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548473A Pending JP2008525477A (ja) | 2004-12-22 | 2005-12-22 | Ｇｌｐ−１アゴニスト、組成物、方法および使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070128193A1 (enExample) |
| EP (1) | EP1843788A4 (enExample) |
| JP (1) | JP2008525477A (enExample) |
| KR (1) | KR20070090036A (enExample) |
| CN (1) | CN101415439A (enExample) |
| AU (1) | AU2005337493A1 (enExample) |
| BR (1) | BRPI0519241A2 (enExample) |
| CA (1) | CA2592065A1 (enExample) |
| CR (1) | CR9266A (enExample) |
| EA (1) | EA200701362A1 (enExample) |
| IL (1) | IL183940A0 (enExample) |
| MX (1) | MX2007007602A (enExample) |
| NI (1) | NI200700158A (enExample) |
| NO (1) | NO20073814L (enExample) |
| SG (1) | SG158158A1 (enExample) |
| WO (1) | WO2007046834A2 (enExample) |
| ZA (1) | ZA200706030B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| EP1894591B1 (en) | 2002-03-20 | 2013-06-26 | MannKind Corporation | Cartridge for an inhalation apparatus |
| EP1786784B1 (en) | 2004-08-20 | 2010-10-27 | MannKind Corporation | Catalysis of diketopiperazine synthesis |
| DK2314298T3 (en) | 2004-08-23 | 2015-06-15 | Mannkind Corp | Microparticles comprising diketopiperazinsalte for drug delivery |
| JP2008536881A (ja) * | 2005-04-21 | 2008-09-11 | ガストロテック・ファルマ・アクティーゼルスカブ | Ｇｌｐ−１分子と制吐剤との医薬製剤 |
| BRPI0616071B8 (pt) | 2005-09-14 | 2021-05-25 | Mannkind Corp | métodos de revestir uma micropartícula cristalina pré-formada em suspensão com um agente ativo |
| WO2007081654A2 (en) * | 2005-12-28 | 2007-07-19 | Zoltan Laboratories Llc | Compositions and methods to enhance viability and function of islet cells |
| IN2015DN00888A (enExample) | 2006-02-22 | 2015-07-10 | Mannkind Corp | |
| TW200843794A (en) * | 2006-12-21 | 2008-11-16 | Centocor Inc | Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles |
| WO2008092209A1 (en) * | 2007-02-01 | 2008-08-07 | Arana Therapeutics Limited | Protein construct with improved properties |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| TWI592178B (zh) | 2008-06-13 | 2017-07-21 | 曼凱公司 | 用於藥物傳輸之乾粉吸入器及系統 |
| MX2010014240A (es) | 2008-06-20 | 2011-03-25 | Mankind Corp | Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion. |
| TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| US20110020392A1 (en) * | 2008-10-14 | 2011-01-27 | Salubrious Pharmaceutical, Llc | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers |
| EP3677275B1 (de) | 2008-10-17 | 2024-06-12 | Sanofi-Aventis Deutschland GmbH | Kombination von einem insulin und einem glp-1-agonisten |
| US8748377B2 (en) | 2008-12-10 | 2014-06-10 | Glaxosmithkline Llc | Pharmaceutical compositions |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| EP2405963B1 (en) | 2009-03-11 | 2013-11-06 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| TWI547487B (zh) | 2009-06-12 | 2016-09-01 | 曼凱公司 | 具限定比表面積之二酮基哌微粒子 |
| CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
| PL2498802T3 (pl) | 2009-11-13 | 2015-06-30 | Sanofi Aventis Deutschland | Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę |
| ES2965209T3 (es) | 2009-11-13 | 2024-04-11 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina |
| US8691763B2 (en) | 2010-05-04 | 2014-04-08 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| RU2604067C2 (ru) | 2010-05-13 | 2016-12-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| RU2571331C1 (ru) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
| EP2588126A4 (en) | 2010-06-24 | 2015-07-08 | Univ Indiana Res & Tech Corp | AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS |
| JP6199186B2 (ja) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用 |
| JP2014502984A (ja) * | 2011-01-19 | 2014-02-06 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１組成物 |
| US8925726B2 (en) | 2011-04-01 | 2015-01-06 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| US9950038B2 (en) * | 2011-08-05 | 2018-04-24 | The Trustees Of The Universiy Of Pennsylvania | Methods and compositions for inhibiting delayed graft function |
| TWI608847B (zh) | 2011-08-29 | 2017-12-21 | 賽諾菲阿凡提斯德意志有限公司 | 用於控制糖尿病二型病患血糖的醫藥組合物 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| JP6018640B2 (ja) | 2011-10-24 | 2016-11-02 | マンカインド コーポレイション | 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム |
| EP2780031B1 (en) | 2011-11-17 | 2018-03-07 | Indiana University Research and Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| CA2864655A1 (en) * | 2012-03-01 | 2013-09-06 | Yeda Research And Development Co. Ltd. | Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes |
| ES2624294T3 (es) | 2012-07-12 | 2017-07-13 | Mannkind Corporation | Sistemas de suministro de fármacos en polvo seco |
| EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
| KR102246914B1 (ko) | 2013-03-15 | 2021-04-30 | 맨카인드 코포레이션 | 미세결정성 디케토피페라진 조성물 및 방법 |
| ES2709339T3 (es) | 2013-04-03 | 2019-04-16 | Sanofi Sa | Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada |
| MX375448B (es) | 2013-07-18 | 2025-03-06 | Mannkind Corp | Composiciones farmacéuticas en polvo seco estables al calor y métodos. |
| WO2015021064A1 (en) | 2013-08-05 | 2015-02-12 | Mannkind Corporation | Insufflation apparatus and methods |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| ES2949095T3 (es) | 2014-12-12 | 2023-09-25 | Sanofi Aventis Deutschland | Formulación de relación fija de insulina glargina/lixisenatida |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| EP3289074B1 (en) * | 2015-04-28 | 2023-10-04 | Université de Strasbourg | Clinical gene signature-based human cell culture model and uses thereof |
| CN105504026B (zh) * | 2015-12-24 | 2018-12-07 | 广东医科大学 | 一种pac1-r和glp-1r的双向激动剂ot23及应用 |
| WO2017211321A1 (zh) * | 2016-06-08 | 2017-12-14 | 上海交通大学医学院 | 增强激动型抗体活性的抗体重链恒定区序列 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| US20230183335A1 (en) | 2020-06-03 | 2023-06-15 | Københavns Universitet | Glp1r agonist nmdar antagonist conjugates |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| NZ525577A (en) * | 2000-12-07 | 2005-05-27 | Lilly Co Eli | Glucagon-Like Peptide 1 heterologous fusion proteins for the treatment of non-insulin dependent diabetes mellitus |
| US20020187926A1 (en) * | 2001-03-07 | 2002-12-12 | Knudsen Liselotte Bjerre | Combined use of derivatives of GLP-1 analogs and PPAR ligands |
| AU2003256336A1 (en) * | 2002-06-28 | 2004-01-19 | Centocor, Inc. | Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| AU2005231359A1 (en) * | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Human GLP-1 mimetibodies, compositions, methods and uses |
-
2005
- 2005-12-22 CA CA002592065A patent/CA2592065A1/en not_active Abandoned
- 2005-12-22 MX MX2007007602A patent/MX2007007602A/es not_active Application Discontinuation
- 2005-12-22 CN CNA2005800484969A patent/CN101415439A/zh active Pending
- 2005-12-22 WO PCT/US2005/046602 patent/WO2007046834A2/en not_active Ceased
- 2005-12-22 EA EA200701362A patent/EA200701362A1/ru unknown
- 2005-12-22 AU AU2005337493A patent/AU2005337493A1/en not_active Abandoned
- 2005-12-22 JP JP2007548473A patent/JP2008525477A/ja active Pending
- 2005-12-22 US US11/315,728 patent/US20070128193A1/en not_active Abandoned
- 2005-12-22 BR BRPI0519241-2A patent/BRPI0519241A2/pt not_active Application Discontinuation
- 2005-12-22 SG SG200908512-7A patent/SG158158A1/en unknown
- 2005-12-22 KR KR1020077016979A patent/KR20070090036A/ko not_active Withdrawn
- 2005-12-22 EP EP05858658A patent/EP1843788A4/en not_active Withdrawn
-
2007
- 2007-06-14 IL IL183940A patent/IL183940A0/en unknown
- 2007-06-19 NI NI200700158A patent/NI200700158A/es unknown
- 2007-07-20 NO NO20073814A patent/NO20073814L/no not_active Application Discontinuation
- 2007-07-20 CR CR9266A patent/CR9266A/es not_active Application Discontinuation
- 2007-07-20 ZA ZA200706030A patent/ZA200706030B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008525477A5 (enExample) | ||
| ES2925098T3 (es) | Activador triple que activa el receptor de glucagón, GLP-1 Y GIP | |
| ES2875748T3 (es) | Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de la obesidad que los comprende | |
| ES2646545T3 (es) | Métodos y composiciones basadas en conjugados de toxina diftérica-interleucina-3 | |
| JP6200025B2 (ja) | 心臓病の処置 | |
| US10786551B2 (en) | Use of interleukin-22 in the treatment of fatty liver disease | |
| ES2732291T3 (es) | Péptidos terapéuticos | |
| JP2006515351A5 (enExample) | ||
| JP2007508011A5 (enExample) | ||
| KR20170078668A (ko) | 이중 glp-1r 및 glp-2r 작용제 활성을 갖는 조성물 및 펩티드 | |
| ES2968038T3 (es) | Agonista GLP-1R de acción prolongada como terapia de afecciones neurológicas y neurodegenerativas | |
| MX2014013319A (es) | Análogos de péptido-2 tipo glucagón (glp-2). | |
| JPWO2015147240A1 (ja) | 敗血症の予防治療剤 | |
| TW201934571A (zh) | Ｆｇｆ２１變體、融合蛋白及其應用 | |
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| TW200843794A (en) | Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles | |
| ES2970116T3 (es) | Composición farmacéutica para tratar la sarcopenia agonista del receptor del péptido de tipo 1 similar al glucagón | |
| CN101466399B (zh) | 稳定的胰岛素样生长因子多肽 | |
| JP2020533302A (ja) | 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１ | |
| CN1655675A (zh) | 利用三叶肽的联合治疗 | |
| JP2009526750A5 (enExample) | ||
| JP2011517548A5 (enExample) | ||
| TWI496579B (zh) | 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途 | |
| JP2021505656A (ja) | グルカゴン様ペプチド | |
| US20170071912A1 (en) | Polyamide Compound and Pharmaceutical Composition for Treating Mitochondrial Genetic Diseases |